Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
8
×
boston blog main
clinical trials
8
×
life sciences
national blog main
boston top stories
fda
drugs
national top stories
san francisco blog main
alnylam pharmaceuticals
biotech
new york blog main
new york top stories
patisiran
rna interference
san francisco top stories
akcea therapeutics
avapritinib
blueprint medicines
deals
hereditary transthyretin amyloidosis
inotersen
investing
onpattro
san diego blog main
san diego top stories
svb leerink
tafamidis
vyndaqel
acute hepatic porphyrias
akin akinc
akouos
aldehyde
aldeyra therapeutics
allergic conjunctivitis
allopregnanolone
aminolevulinic acid
andrew berens
andrew fire
What
fda
8
×
drug
medicine
alnylam
approval
approved
ago
blueprint
cancer
filing
medicines
new
pharmaceuticals
plans
rna
rnai
seek
specifically
therapeutics
type
affects
afternoon
aldeyra
alnylam’s
americans
announced
approve
awaits
biological
brexanolone
candidate
chasing
closer
crossed
currently
data
date
deadly
decades
deciphera
Language
unset
Current search:
boston
×
fda
×
" clinical trials "
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision